{
    "nctId": "NCT04842812",
    "briefTitle": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
    "officialTitle": "Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors",
    "overallStatus": "RECRUITING",
    "conditions": "Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer, Brain Tumor, Solid Tumor, Adult, PD1, CTLA4",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Safety of TILs/CAR-TILs treatment in advanced solid cancers",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with advanced cancers that failed to current available therapies;\n2. Life expectancy \\>12 weeks;\n3. Adequate heart, lung, liver, kidney functions;\n4. Available for tumor biopsy or cancerous effusions;\n5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity;\n3. Active infectious disease related to bacteria, virus, fungi, et al;\n4. Other severe diseases that the investigators consider not appropriate;\n5. Pregnant or lactating women;\n6. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);\n7. Other conditions that the investigators consider not appropriate.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}